SGLT-2 Inhibitors, An Issue of Heart Failure Clinics: The Clinics: Internal Medicine, cartea 18-4
Editat de Deepak L. Bhatt, Ragavendra R. Baligaen Limba Engleză Hardback – 11 oct 2022
Din seria The Clinics: Internal Medicine
- 5%
Preț: 394.41 lei - 15%
Preț: 503.11 lei - 5%
Preț: 608.74 lei - 5%
Preț: 466.20 lei - 5%
Preț: 633.40 lei - 5%
Preț: 574.16 lei - 5%
Preț: 599.73 lei - 5%
Preț: 600.12 lei - 5%
Preț: 599.98 lei - 5%
Preț: 600.03 lei - 5%
Preț: 600.34 lei - 5%
Preț: 599.27 lei - 5%
Preț: 616.99 lei - 5%
Preț: 464.77 lei - 5%
Preț: 465.73 lei - 5%
Preț: 466.02 lei - 5%
Preț: 536.41 lei - 5%
Preț: 535.73 lei - 5%
Preț: 466.46 lei - 5%
Preț: 532.76 lei - 5%
Preț: 468.73 lei - 5%
Preț: 465.73 lei - 5%
Preț: 449.04 lei - 5%
Preț: 451.15 lei - 5%
Preț: 575.59 lei - 5%
Preț: 534.89 lei - 5%
Preț: 551.34 lei - 5%
Preț: 582.64 lei - 5%
Preț: 515.34 lei - 5%
Preț: 465.10 lei - 5%
Preț: 600.54 lei - 5%
Preț: 599.72 lei - 5%
Preț: 590.42 lei - 5%
Preț: 481.95 lei - 25%
Preț: 463.36 lei - 5%
Preț: 634.80 lei - 25%
Preț: 461.96 lei - 5%
Preț: 666.99 lei - 5%
Preț: 666.70 lei - 5%
Preț: 633.37 lei - 5%
Preț: 637.44 lei - 5%
Preț: 666.81 lei - 5%
Preț: 670.00 lei - 5%
Preț: 337.63 lei - 5%
Preț: 793.48 lei - 5%
Preț: 667.38 lei - 5%
Preț: 666.84 lei - 5%
Preț: 655.22 lei - 5%
Preț: 633.37 lei - 5%
Preț: 633.59 lei
Preț: 445.81 lei
Preț vechi: 469.27 lei
-5% Nou
Puncte Express: 669
Preț estimativ în valută:
78.88€ • 91.89$ • 68.88£
78.88€ • 91.89$ • 68.88£
Carte tipărită la comandă
Livrare economică 12-26 ianuarie 26
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9780323960465
ISBN-10: 0323960464
Pagini: 240
Dimensiuni: 178 x 254 mm
Greutate: 0.54 kg
Editura: Elsevier
Seria The Clinics: Internal Medicine
ISBN-10: 0323960464
Pagini: 240
Dimensiuni: 178 x 254 mm
Greutate: 0.54 kg
Editura: Elsevier
Seria The Clinics: Internal Medicine
Cuprins
Glucose-Lowering and Metabolic Effects of SGLT2 Inhibitors
Renoprotective Effects of SGLT2 Inhibitors
SGLT2 Inhibitors in Type 2 Diabetes Mellitus
SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction: A Paradigm Shift Toward Dual Cardio-Renal Protection
SGLT2 Inhibitors and Heart Failure with Preserved Ejection Fraction
SGLT2 Inhibitors in Heart Failure: Early Initiation to Achieve Rapid Clinical Benefits
Sodium-Glucose Cotransporter-2 Inhibitors: Impact on Atherosclerosis and Atherosclerotic Cardiovascular Disease Events
SGLT2 Inhibitors and Peripheral Vascular Events: A Review of the Literature
Sodium-glucose Cotransporter 2 Inhibitors and Nonalcoholic Fatty Liver Disease
SGLT2 Inhibitors and Safety in Older Patients
Sodium Glucose Cotransporter 2 Inhibitors, Amputation Risk, and Fracture Risk
Renoprotective Effects of SGLT2 Inhibitors
SGLT2 Inhibitors in Type 2 Diabetes Mellitus
SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction: A Paradigm Shift Toward Dual Cardio-Renal Protection
SGLT2 Inhibitors and Heart Failure with Preserved Ejection Fraction
SGLT2 Inhibitors in Heart Failure: Early Initiation to Achieve Rapid Clinical Benefits
Sodium-Glucose Cotransporter-2 Inhibitors: Impact on Atherosclerosis and Atherosclerotic Cardiovascular Disease Events
SGLT2 Inhibitors and Peripheral Vascular Events: A Review of the Literature
Sodium-glucose Cotransporter 2 Inhibitors and Nonalcoholic Fatty Liver Disease
SGLT2 Inhibitors and Safety in Older Patients
Sodium Glucose Cotransporter 2 Inhibitors, Amputation Risk, and Fracture Risk